Sector News

Merck to acquire German contract development company AmpTec

January 10, 2021
Life sciences

Merck has announced the acquisition of Germany-based, mRNA contract development and manufacturing organisation (CDMO) AmpTec.

The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.

Merck CEO and executive board chairman Stefan Oschmann said: “The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases.

“By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.”

Merck’s Life Science business sector’s SAFC portfolio includes lipids, which serve as major components for mRNA therapeutics formulation including for Covid-19 vaccines.

The company is partnering with over 50 vaccine manufacturers to aid in Covid-19 vaccine, treatment and service development and production efforts.

Another vital component of mRNA manufacturing is PCR technology. AmpTec utilises a distinguished PCR-based technology for producing mRNA.

As compared to others, PCR-based manufacturing technology has benefits such as homogeneity, purity, activity and flexibility, increased quality, better performance, as well as adaptable capping options to reach specific performance needs.

Apart from its specialisation in mRNA technology, AmpTec has a diagnostics business focused on making customised long RNAs and DNAs for in vitro diagnostics, which will complement existing Merck portfolio.

AmpTec managing directors and founders Guido Krupp and Peter Scheinert said: “AmpTec’s more than 40 employees are thrilled to join Merck and are confident that our PCR-based technology and combined expertise will allow us to offer customers innovative technologies, products and services to help advance life-enhancing therapeutics.”

Financial terms of the deal remain undivulged.

Last November, Merck signed a definitive agreement to acquire all outstanding shares of clinical-stage biopharmaceutical firm OncoImmune through a subsidiary, for an upfront payment of $425m in cash.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).